The data, from scientists at Imperial College London, suggests the technology can generate immune responses against COVID-19 in up to 87 per cent of people, even at extremely low dose levels – the lowest of any COVID-19 vaccine candidate worldwide.
The technology uses genetic code called self-amplifying RNA (saRNA). This genetic information holds instructions to make a protein found on the outside of the coronavirus, called the spike protein.
Once injected into the muscle of the arm, the cells make this spike protein, enabling the immune system to generate defences against the virus.
The team, who published their data on a pre-print server, are now refining the technology to produce future vaccines and boosters against COVID-19, and emerging variants.
The team are modifying the technology to produce a more consistent and strong response, even at very low dose levels, and will pursue trials with updated vaccine candidates.
imperial.ac.uk/news/222553/...
SSRN Electronic Journal. Pre-print Research Paper (PDF file):
